Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics
GRTS Price/Volume Stats
| Current price | $0.75 | 52-week high | $3.33 |
| Prev. close | $0.77 | 52-week low | $0.67 |
| Day low | $0.74 | Volume | 3,114,300 |
| Day high | $0.79 | Avg. volume | 2,870,900 |
| 50-day MA | $2.05 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 73.08M |
GRTS Stock Price Chart Interactive Chart >
Gritstone Oncology, Inc. (GRTS) Company Bio
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.
Latest GRTS News From Around the Web
Below are the latest news stories about GRITSTONE BIO INC that investors may wish to consider to help them evaluate GRTS as an investment opportunity.
Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved DrasticallyCelebrations may be in order for Gritstone bio, Inc. ( NASDAQ:GRTS ) shareholders, with the analysts delivering a... |
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase an aggregate of 42,000 shares of its common stock with an exercise price of $1.53, which is equal to the closing price of Gritstone’s common stock on December 1, 2023, th |
Gritstone bio to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation: |
Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine DevelopmentAdvancements in COVID-19 and Cancer Vaccine Programs Amid Increased R&D Spending |
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating samRNA candidate versus an approved COVID-19 vaccine -- -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating Gritstone’s personalized cancer vaccine (PCV), GRANITE, in first-line metastatic, microsatellite stable colorectal cancer (MSS-CRC) remain expected in 1 |
GRTS Price Returns
| 1-mo | -72.32% |
| 3-mo | -70.82% |
| 6-mo | -62.87% |
| 1-year | -71.70% |
| 3-year | -91.46% |
| 5-year | -94.54% |
| YTD | -63.24% |
| 2023 | -40.87% |
| 2022 | -73.17% |
| 2021 | 226.40% |
| 2020 | -56.08% |
| 2019 | -41.94% |
Continue Researching GRTS
Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...